---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-26-000020"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2026-04-21T23:59:59+00:00"
generated_at: "2026-05-15T05:10:05.677689+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Director Jeffrey Sherman to retire from Xeris Biopharma board at 2026 annual meeting

## Summary
- Dr. Jeffrey Sherman notified Board of his retirement and will not stand for reelection at the 2026 Annual Meeting.
- Sherman will continue serving on Compensation and Nominating/Governance committees until his term expires.
- Board reduced from eight to seven directors effective after Sherman's term ends at the 2026 Annual Meeting.
- Sherman stated his retirement is not due to any disagreement with the company or its management.

## SEC filing metadata
- accession: 0001867096-26-000020
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2026-04-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000020/0001867096-26-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000020/xers-20260420.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-26-000020
- JSON: https://secwatch.observer/filing/0001867096-26-000020.json
- Plain text: https://secwatch.observer/filing/0001867096-26-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.